Nevirapina Tarbis Farma (Nevirapine)

Nevirapine, the active ingredient in Nevirapina Tarbis Farma, is a non‑nucleoside reverse transcriptase inhibitor presented as a tablet for oral use. It inhibits HIV‑1 replication by targeting the reverse transcriptase enzyme and is indicated for the treatment of HIV‑1 infection in adults and adolescents, forming part of combination antiretroviral therapy regimens.

GNH USA supplies Nevirapina Tarbis Farma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Nevirapine is used in the management of HIV‑1 infection, a viral disease that requires suppression of viral replication.

- HIV‑1 infection (treatment‑naïve patients): Reduces viral load and improves immune function when used as part of first‑line combination therapy. - HIV‑1 infection (treatment‑experienced patients): Provides an alternative mechanism of action for patients with resistance to other drug classes. - HIV‑1 infection (pregnant women): Used under specialist supervision to maintain maternal viral suppression and reduce mother‑to‑child transmission.

Nevirapine may cause a range of adverse reactions, ranging from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal discomfort. - Headache: transient mild headaches. - Fatigue: general tiredness. - Diarrhea: loose stools. - Elevated liver enzymes: mild hepatic enzyme changes.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatic failure: signs of liver toxicity such as jaundice. - Severe hypersensitivity: fever, eosinophilia, and systemic symptoms. - Acute liver injury: marked elevation of transaminases. - Anaphylaxis: rare but life‑threatening allergic reaction. - Hematologic abnormalities: neutropenia or anemia.

Nevirapine requires careful monitoring and specific safety measures.

- Liver function monitoring: check transaminases before initiation and regularly thereafter. - Pregnancy considerations: use only when benefits outweigh risks and under specialist guidance. - Hepatic impairment: avoid or adjust use in patients with pre‑existing liver disease. - Concomitant CYP inducers: avoid strong inducers that may reduce nevirapine exposure. - Dermatologic reactions: discontinue promptly if severe rash or mucosal involvement develops. - Store at room temperature: keep in the original container, protect from moisture and direct heat.

Nevirapine interacts with several drug classes and may alter their effectiveness.

Major Interactions (Avoid): - Rifampicin: potent CYP3A4 inducer that markedly reduces nevirapine plasma levels. - Protease inhibitors (e.g., ritonavir): can increase nevirapine concentrations and risk of toxicity. - St. John’s wort: herbal CYP inducer that lowers nevirapine exposure.

Moderate Interactions (Monitor Closely): - Oral contraceptives: nevirapine may reduce hormonal efficacy; consider alternative contraception. - Warfarin: potential alteration of anticoagulant effect; monitor INR. - Other antiretrovirals: dose adjustments may be needed when combined with certain NRTIs or integrase inhibitors.